Literature DB >> 1736876

Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection.

H W Kwak1, D J D'Amico.   

Abstract

The intravitreal injection of steroids may be potentially useful in the treatment of endophthalmitis and other ocular inflammatory diseases. The retinal toxicity and intraocular turnover of aqueous solutions of dexamethasone sodium phosphate in doses ranging from 440 to 4000 micrograms were evaluated in the rabbit; evaluation was also performed for a 0.1-mL injection of a commercially available preparation (dexamethasone phosphate [Decadron] injection, 4 mg/mL). After the 440-micrograms dose, a transient increase in staining of the Müller cells was observed, which normalized after 2 days. Progressively higher doses resulted in an increasing spectrum of disorganization in Müller and other retinal cells. The half-life of the intravitreally injected drug was 3.48 hours. These findings suggest a primary interference in Müller cell function, possibly through dexamethasone-induced alterations in retinal glutamate or glucose metabolism.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1736876     DOI: 10.1001/archopht.1992.01080140115038

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  56 in total

1.  Intraocular pressure after intravitreal injection of triamcinolone acetonide.

Authors:  J B Jonas; I Kreissig; R Degenring
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

2.  Ocular pharmacokinetic study of a corticosteroid by 19F MR.

Authors:  Xin Liu; S Kevin Li; Eun-Kee Jeong
Journal:  Exp Eye Res       Date:  2010-06-09       Impact factor: 3.467

Review 3.  Biodegradable implants for sustained drug release in the eye.

Authors:  Susan S Lee; Patrick Hughes; Aron D Ross; Michael R Robinson
Journal:  Pharm Res       Date:  2010-06-10       Impact factor: 4.200

4.  Prediction of the vitreal half-life of small molecular drug-like compounds.

Authors:  Heidi Kidron; Eva M Del Amo; Kati-Sisko Vellonen; Arto Urtti
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

Review 5.  [Intravitreal implants: drug carriers and carriers of hope?].

Authors:  S Winterhalter; P Ruokonen; K H van der Velden; U Pleyer; A M Joussen
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

6.  Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

Authors:  J B Jonas; I Kreissig; P Hugger; G Sauder; S Panda-Jonas; R Degenring
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

7.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

8.  Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle.

Authors:  L Cheng; E Anglin; F Cunin; D Kim; M J Sailor; I Falkenstein; A Tammewar; W R Freeman
Journal:  Br J Ophthalmol       Date:  2008-05       Impact factor: 4.638

9.  Intraocular dexamethasone produces a harmful effect on treatment of experimental Staphylococcus aureus endophthalmitis.

Authors:  T A Meredith; H E Aguilar; C Drews; A Sawant; S Gardner; L A Wilson; H E Grossniklaus
Journal:  Trans Am Ophthalmol Soc       Date:  1996

Review 10.  Clinical Applications of Dexamethasone for Aged Eyes.

Authors:  Beatriz Abadia; Pilar Calvo; Antonio Ferreras; Fran Bartol; Guayente Verdes; Luis Pablo
Journal:  Drugs Aging       Date:  2016-09       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.